Age-stratified risk of major adverse cardiovascular events with JAK inhibitors in rheumatoid arthritis: A nationwide cohort study.
BACKGROUND The cardiovascular safety of Janus kinase inhibitors (JAKi) compared with biological disease-modifying antirheumatic drugs (bDMARDs) and conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in rheumatoid arthritis (RA) remains debated. We aimed to evaluate the risk of major adverse cardiov...